KBLB Kraig Biocraft Laboratories Inc.

Kraig Biocraft Laboratories Brings Leading Sericulture Expert from India for Launch of Spring Production Trials

Kraig Biocraft Laboratories Brings Leading Sericulture Expert from India for Launch of Spring Production Trials

ANN ARBOR, Mich., March 19, 2024 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("Kraig Labs" or "the Company"), announces today that Dr. Nirmal Kumar, a globally recognized expert in sericulture, will join the Company’s Senior Management in Vietnam to supervise the start of the spring production trials and the launch of the BAM-1 hybrid.

Dr. Nirmal Kumar gained recognition as a leading authority in the breeding and rearing of silkworms through his 37 years of work at the Central Sericulture Research & Training Institute ("CSRTI") in India. He specializes in research, training, and testing of silkworm breeds, mulberry cultivation, and rearing technologies. Dr. Nirmal Kumar joined the Kraig Labs team as a senior consultant in November of 2023, bringing world-class expertise in silkworm breeding and commercial scale rearing to the Company.

Dr. Nirmal Kumar will join senior management to oversee operations and kick off the 2024 production season. He is tasked with reviewing the Company's production operations and that of its third party contract manufacturers. He will provide guidance and training to the team and oversee the rearing of the first generation of BAM-1 parent lines. He will also assist senior management in outlining the blueprints for the planned continued expansion of production capacity in Vietnam.

"Dr. Nirmal Kumar brings a wealth of firsthand knowledge and expertise. We are very excited to have him working side by side with our team as we mark this pivotal milestone for the commercialization of recombinant spider silk," said Founder and CEO of Kraig Labs, Kim Thompson.

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (), a reporting biotechnology company is the leading developer of recombinant spider silk-based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company's future and expectations other than historical facts are "forward-looking statements." These statements are made on the basis of management's current views and assumptions. As a result, there can be no assurance that management's expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as "believes," "plans," "expects," "anticipates," "foresees," "estimated," "hopes," "if," "develops," "researching," "research," "pilot," "potential," "could" or other words or phrases of similar import. Forward looking statements include descriptions of the Company's business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495



EN
19/03/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Kraig Biocraft Laboratories Inc.

 PRESS RELEASE

Kraig Biocraft Laboratories Deploys Over 700,000 BAM-1 Alpha Productio...

Kraig Biocraft Laboratories Deploys Over 700,000 BAM-1 Alpha Production Hybrids, Achieving Key Milestone in its Aggressive Scale-Up Plan ANN ARBOR, Mich., March 30, 2026 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("the Company", "Kraig Labs", or "Kraig's"), a world leader in spider silk technology*, today announced the successful deployment of more than 700,000 BAM-1 Alpha production hybrids of its previously reported 1,000,000 egg inventory. These silkworms are now in active production. This achievement underscores the Company's continued execution of its previou...

 PRESS RELEASE

Kraig Biocraft Laboratories Increases R&D Capacity, as Project Atlas B...

Kraig Biocraft Laboratories Increases R&D Capacity, as Project Atlas Breakthroughs Creating New Spider Silk Transgenics ANN ARBOR, Mich., March 23, 2026 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("the Company", "Kraig Labs", or "Kraig's"), a world leader in spider silk technology*, today announced a significant expansion of its research and development capacity designed to keep pace with rapid progress of its advanced materials initiative, Project Atlas. The Company has expanded its laboratory capabilities, onboarding new scientific personnel and the deploymen...

 PRESS RELEASE

Engineered Silkworms Spin Spider Silk as Biotech Firm Targets Commerci...

Engineered Silkworms Spin Spider Silk as Biotech Firm Targets Commercial Scale DENVER, March 18, 2026 (GLOBE NEWSWIRE) --  -- A biotechnology company developing genetically engineered silkworms says it’s moving toward commercial production of spider silk, a material long sought by researchers for its unusual combination of strength and elasticity. Kraig Biocraft Laboratories (OTCQB: KBLB) deployed one million genetically engineered silkworm eggs across multiple production facilities in Vietnam as part of a Spring scale-up effort that could eventually produce around 10 metric tons of reco...

 PRESS RELEASE

24/7 Market News: Kraig Labs the Bootstrapped Unicorn in the Making

24/7 Market News: Kraig Labs the Bootstrapped Unicorn in the Making DENVER, March 11, 2026 (GLOBE NEWSWIRE) -- -- In technology and biotechnology, “unicorn” status is typically reserved for private companies valued at $1 billion or more; often backed by major venture rounds, institutional syndicates, and aggressive capital deployment strategies. But what happens when a company advances a platform with billion-dollar potential without the backing of Silicon Valley mega-funding? That question is increasingly being asked about Kraig Biocraft Laboratories (OTCQB: KBLB). More than a decade ...

 PRESS RELEASE

Kraig Biocraft Laboratories Targets New Industrial and Defense Biomate...

Kraig Biocraft Laboratories Targets New Industrial and Defense Biomaterials as "Project Atlas" Hits Major Milestone ANN ARBOR, Mich., March 05, 2026 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("the Company", "Kraig Labs", or "Kraig's"), a world leader in spider silk technology*, today announced a major milestone in "Project Atlas", the Company's next-generation bioengineering initiative aimed at creating entirely new classes of materials for industrial and defense applications. Kraig Labs first disclosed the existence of Project Atlas on January 19th, 2026, when ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch